免疫检查点抑制剂介导的心肌炎：心脏中的CTLA4、PD1和LAG3

文章预览

SCI 1 August 2024 Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart (Nature Reviews Cancer, IF: 72.5) Amir Z. Munir, Alan Gutierrez, Juan Qin, Andrew H. Lichtman & Javid J. Moslehi CORRESPONDENCE TO: Javid.moslehi@ucsf.edu Abstract 摘要 Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all patients with cancer eligible for treatment with ICIs. However, patients on ICI therapy are at risk for immune-related toxicities that can affect any organ. Inflammation of the heart muscle, known as myocarditis, resulting from ICI targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) is an infrequent but potentially fatal complication. ICI-mediated myocarditis (ICI-myocarditis) is a growing clinical entity given the widespread use of ICIs, its increased clinical recognition and growing use of combination ICI treatment, a well-documented risk factor for ICI- ………………………………